Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Approvals: Rinvoq Cleared For RA

AbbVie's Selective JAK Inhibitor A Driver Of Future Growth

Executive Summary

AbbVie’s upadacitinib has become the latest JAK inhibitor to be approved in the EU for active rheumatoid arthritis, and its selectivity could allow it to compete effectively with established therapies including other JAK inhibitors, TNF-inhibiting biologics and biosimilars.

You may also be interested in...



EMA Recommends Caution For Pfizer's Xeljanz

The European Medicines Agency's drug safety committee has concluded that Pfizer's Xeljanz could increase the risk of blood clots in patients who are already at high risk. The committee has also recommended restrictions on the use of Sanofi's multiple sclerosis drug, Lemtrada.

AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval

Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.

Janssen's Tremfya Gains Psoriatic Arthritis Indication In EU

The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel